Consolidated Financial Results for the Six Months Ended June 30, 2026 (Under Japanese GAAP)
Filed with TSE · · 8 pages · English
(Percentages indicate year-on-year changes.) Note: Comprehensive income For the six months ended June 30, 2026: For the six months ended June 30, 2025: (2) Consolidated financial position Reference: Equity ¥208,846 million As of December 31, 2025: ¥210,206 million 2. Cash dividends Note: Revisions to the forecast of cash dividends most recently announced: None 3. Forecast of consolidated financial
Kobayashi Pharmaceutical Co., Ltd. on 6ix
In the deck
Earlier from Kobayashi Pharmaceutical
- FY2026（January 1, 2026 - December 31, 2026）1Q Financial Statement Summary
- Financial Overview for First Quarter of Fiscal 2026(Fiscal Year Ending December 31, 2026)
- Financial Overview for Third Quarter of Fiscal 2025(Fiscal Year Ending December 31, 2025)
- FY2025（January 1, 2025 - December 31, 2025）1Q Financial Statement
- Financial Overview for First Quarter of Fiscal 2025(Fiscal Year Ending December 31, 2025)
Later from Kobayashi Pharmaceutical
All Kobayashi Pharmaceutical news releasesFollow Kobayashi Pharmaceutical into a list and get an email when it puts out news.
Follow Kobayashi Pharmaceutical